share_log

CEO Ping Li, Jiangsu Nanfang Medical Co., Ltd.'s (SHSE:603880) Largest Shareholder Sees Value of Holdings Go Down 23% After Recent Drop

CEO Ping Li, Jiangsu Nanfang Medical Co., Ltd.'s (SHSE:603880) Largest Shareholder Sees Value of Holdings Go Down 23% After Recent Drop

江蘇南方醫療股份有限公司首席執行官李平s (SHSE: 603880) 最大股東預計,持股價值在最近下跌後將下降23%
Simply Wall St ·  2023/05/10 19:23

Key Insights

主要見解

  • Jiangsu Nanfang Medical's significant insider ownership suggests inherent interests in company's expansion
  • 52% of the business is held by the top 4 shareholders
  • Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock
  • 江秀克南方醫療的重大內部人持股表明了公司擴張的內在利益
  • 52%的業務由前四大股東持有
  • 所有權研究,結合過去的業績數據,可以幫助您更好地瞭解股票的機會

If you want to know who really controls Jiangsu Nanfang Medical Co., Ltd. (SHSE:603880), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are individual insiders with 55% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

如果你想知道誰真正控制了江秀克南方醫療股份有限公司(上海證券交易所代碼:603880),那麼你就得看看它的股票登記簿的構成。而持有這塊蛋糕最大份額的是擁有55%股權的個人內部人士。換句話說,該集團面臨著最大的上行潛力(或下行風險)。

As market cap fell to CN¥1.2b last week, insiders would have faced the highest losses than any other shareholder groups of the company.

隨著上週市值跌至12億元人民幣,內部人士將面臨比該公司其他任何股東群體都要高的損失。

Let's delve deeper into each type of owner of Jiangsu Nanfang Medical, beginning with the chart below.

讓我們從下面的圖表開始,更深入地研究江秀克南方醫療的每一種類型的所有者。

Check out our latest analysis for Jiangsu Nanfang Medical

查看我們對江秀克南方醫療的最新分析

ownership-breakdown
SHSE:603880 Ownership Breakdown May 10th 2023
上海證交所:603880所有權明細2023年5月10日

What Does The Institutional Ownership Tell Us About Jiangsu Nanfang Medical?

關於江秀克南方醫療,機構持股告訴了我們什麼?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構通常在向自己的投資者報告時,以基準來衡量自己,因此一旦一隻股票被納入主要指數,它們往往會對這只股票變得更加熱情。我們預計,大多數公司都會有一些機構登記在冊,特別是在它們正在增長的情況下。

Institutions have a very small stake in Jiangsu Nanfang Medical. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too.

這些機構在江秀克南方醫療的持股比例非常低。這表明該公司受到了一些基金的關注,但目前並不是特別受專業投資者的歡迎。如果業務從現在開始變得更強勁,我們可能會看到更多機構熱衷於購買的情況。當幾家大機構想要同時購買某隻股票時,我們有時會看到股價上漲。下面你可以看到的收益和收入的歷史,可能有助於考慮是否有更多的機構投資者會想要這只股票。當然,還有很多其他因素需要考慮。

earnings-and-revenue-growth
SHSE:603880 Earnings and Revenue Growth May 10th 2023
上海證交所:603880的收益和收入增長2023年5月10日

Jiangsu Nanfang Medical is not owned by hedge funds. The company's CEO Ping Li is the largest shareholder with 41% of shares outstanding. With 5.8% and 3.3% of the shares outstanding respectively, Dong Xu and Yong Ping Li are the second and third largest shareholders.

江秀克南方醫療不屬於對沖基金所有。該公司首席執行長Li是第一大股東,持有41%的流通股。董旭和Li永平分別持有5.8%和3.3%的流通股,是第二大和第三大股東。

Our research also brought to light the fact that roughly 52% of the company is controlled by the top 4 shareholders suggesting that these owners wield significant influence on the business.

我們的研究還揭示了這樣一個事實,即公司約52%的股份由前4名股東控制,這表明這些所有者對業務具有重大影響。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。我們的資訊顯示,分析師沒有對該股進行任何報道,因此它可能鮮為人知。

Insider Ownership Of Jiangsu Nanfang Medical

江秀克南方醫療的內部人所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

不同國家對內部人的定義可能略有不同,但董事會成員總是算數的。公司管理層對董事會負責,董事會應代表股東的利益。值得注意的是,有時最高層管理人員本身也是董事會成員。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟。然而,在某些情況下,太多的權力集中在這個群體中。

It seems that insiders own more than half the Jiangsu Nanfang Medical Co., Ltd. stock. This gives them a lot of power. So they have a CN¥682m stake in this CN¥1.2b business. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

看來,內部人士持有江秀克南方醫療股份有限公司一半以上的股份。這給了他們很大的權力。因此,他們在這筆12億加元的業務中持有6.82億加元的股份。很高興看到這樣的投資水準。你可以在這裡查看這些內部人士最近是否一直在買入。

General Public Ownership

一般公有制

The general public, who are usually individual investors, hold a 42% stake in Jiangsu Nanfang Medical. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

通常為個人投資者的普通公眾持有江秀克南方醫療42%的股份。雖然這群人不一定能發號施令,但它肯定能對公司的運營方式產生真正的影響。

Next Steps:

接下來的步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Be aware that Jiangsu Nanfang Medical is showing 4 warning signs in our investment analysis , and 2 of those are a bit concerning...

我發現看看到底是誰擁有一家公司是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他資訊。請注意,江秀克南方醫療正在展示我們的投資分析中的4個警告信號,其中有兩個是關於...

Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.

當然了這可能不是最值得購買的股票。。所以讓我們來看看這個免費 免費有趣的公司名單。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數位是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數位不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論